US3984384087 - ADR
GRIFOLS SA-ADR
NASDAQ:GRFS (3/28/2024, 8:14:07 PM)
After market: 6.6 -0.08 (-1.2%)6.68
+0.03 (+0.45%)
Grifols SA engages in the production of plasma derivatives. The company is headquartered in Barcelona, Barcelona and currently employs 23,245 full-time employees. The company went IPO on 2006-05-17. The company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
GRIFOLS SA-ADR
C/ Jesus y Maria, 6
Barcelona BARCELONA 08174
P: 34935710000
CEO: Raimon Grifols Roura
Employees: 23245
Website: https://www.grifols.com/
NEW YORK, NY - (NewMediaWire) - March 28, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities. Click Here to Join the Investigation.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are...
NEW YORK, NY - (NewMediaWire) - March 27, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities. Click Here to Join the Investigation.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NEW YORK, NY - (NewMediaWire) - March 22, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities. Click Here to Join the Investigation.
Here you can normally see the latest stock twits on GRFS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: